Not on air · 2 of 3 networks checked
Juisci ads
- juisci.com
- IT Services and IT Consulting
- 35 employees
Juisci’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 55. Watch Juisci on any plan to get each new one in your feed.
Watchlist included in every plan
What Juisci runs
- Single image · LinkedIn
- 4
- Video · LinkedIn
- 2
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksNov 2026 | Checked | Next step |
|---|---|---|---|---|---|
| None recorded | 0 | Checked 7 Nov 2026 | See all 55 ads → | ||
| Meta | Not checked | — | |||
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 1 Nov 2026 | Collect them with the API → |
Juisci has no live LinkedIn ads. We recorded no Google ads on 1 Nov 2026.
Latest ads
- LINKEDIN · IMAGESince 14 Sept 2026
Juisci Healthy Hour: First-line treatment of BRAF V600E metastatic colorectal cancer What's new in first-line therapy for BRAF V600E mCRC? Two experts break down the latest data and what it means in practice. Prof. Van Morris, MD Anderson Cancer Center at Cooper Prof. David TOUGERON, CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS September 22, 5 PM CEST (11 AM ET) 60 minutes: presentation plus live Q&A Register here: https://lnkd.in/gsVNQpsy
- LINKEDIN · IMAGESince 1 Sept 2026
50% objective response with immunotherapy in MSS mCRC > a setting where checkpoint blockade was expected to fail. That phase 1/2 signal, in BRAF V600E disease, is one of several reasons first-line strategy is being rethought. Join Prof. Van K. Morris and Prof. David Tougeron live on September 22, 5:00 PM CEST. For healthcare professionals.
- LINKEDIN · IMAGESince 1 Sept 2026
BRAF V600E mCRC at your next tumor board: first-line sequencing logic, immunotherapy in MSS disease, atypical non-V600 variants, and where ctDNA fits. A 90-minute live session with Prof. Van K. Morris and Prof. David Tougeron, with live Q&A. Tuesday 22 September, 5:00–6:30 PM CEST. For healthcare professionals.
- LINKEDIN · IMAGESince 1 Sept 2026
Prof. Van K. Morris (MD Anderson) and Prof. David Tougeron (Poitiers University Hospital) on first-line treatment in BRAF V600E mCRC > live webinar, September 22. Discovery science from Houston, real-world evidence from Europe: evolving first-line data, immunotherapy in MSS disease, non-V600 variants, ctDNA in the work-up. 90 minutes, live Q&A, in English. Free registration for healthcare professionals.
- LINKEDIN · VIDEOSince 4 Jul 2026
The oncology literature is exploding, and there's no time to read it all. Juisci summarizes the publications that change practice in 2 minutes, to read, listen to, or ask your own questions directly to the study. 200,000+ physicians already use it. 👇
- LINKEDIN · VIDEOSince 3 Jul 2026
The neurology literature is exploding, and there's no time to read it all. Juisci summarizes the publications that change practice in 2 minutes, to read, listen to, or ask your own questions. Example: in refractory generalized myasthenia gravis, a single CD19/BCMA CAR-T drove a systemic immune reset. The summary 👇
6 of 55 adsSign up to see every Juisci ad, filter by format and date, and get alerts on new ones.
See all 55 adsQuestions about Juisci’s ads
Is Juisci running LinkedIn ads?
We recorded no live LinkedIn ads for Juisci on 9 Nov 2026.
How many LinkedIn ads has Juisci run?
LinkedIn’s ad library lists 27 ads for Juisci. We recorded 55 LinkedIn ads for Juisci, first recorded on 24 Sept 2026 and last recorded on 24 Sept 2026.
Does Juisci run Google ads?
We recorded no Google ads for the domain juisci.com on 1 Nov 2026.
Which ad formats does Juisci use?
The 6 LinkedIn ads on this page include 4 image ads and 2 video ads.
Watch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.